Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Debt to Equity (2018 - 2024)

Neurocrine Biosciences (NBIX) has disclosed Debt to Equity for 4 consecutive years, with $0.05 as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Debt to Equity changed N/A year-over-year to $0.05, compared with a TTM value of $0.05 through Mar 2024, changed N/A, and an annual FY2023 reading of $0.08, changed N/A over the prior year.
  • Debt to Equity was $0.05 for Q1 2024 at Neurocrine Biosciences, down from $0.08 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.53 in Q3 2020 and bottomed at $0.05 in Q1 2024.
  • Average Debt to Equity over 3 years is $0.22, with a median of $0.09 recorded in 2023.